4//SEC Filing
Farquharson Andrew 4
Accession 0000950170-23-071467
CIK 0001856725other
Filed
Dec 18, 7:00 PM ET
Accepted
Dec 19, 4:05 PM ET
Size
8.0 KB
Accession
0000950170-23-071467
Insider Transaction Report
Form 4
Farquharson Andrew
Director
Transactions
- Award
Stock Option (Right to Buy)
2023-12-16+101,276→ 101,276 totalExercise: $2.84Exp: 2033-05-24→ Class A Common Stock (101,276 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2023-12-16−101,276→ 0 totalExercise: $4.11Exp: 2033-05-24→ Class A Common Stock (101,276 underlying)
Footnotes (2)
- [F1]The shares subject to the option vest in full on May 25, 2024, subject to the recipient's Continuous Service (as defined in the Issuer's 2021 Equity Incentive Plan) through such vesting date; provided that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Issuer's next annual stockholder meeting or a Change in Control (as defined in the 2021 Equity Incentive Plan).
- [F2]The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 16, 2023 (the "Repricing Date"). Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.84 per share, the closing price of the Issuer's Common Stock on the Repricing Date. There is no change to the expiration dates or the vesting schedule of the repriced options.
Documents
Issuer
Rani Therapeutics Holdings, Inc.
CIK 0001856725
Entity typeother
Related Parties
1- filerCIK 0001865699
Filing Metadata
- Form type
- 4
- Filed
- Dec 18, 7:00 PM ET
- Accepted
- Dec 19, 4:05 PM ET
- Size
- 8.0 KB